Compile Data Set for Download or QSAR
Report error Found 84 Enz. Inhib. hit(s) with all data for entry = 5925
TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2437BDBM2437(US8507533, 157)
Affinity DataKi:  5.55nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100827BDBM100827(US8507533, 374 | US8507533, 151 | US8507533, 138)
Affinity DataKi:  5.75nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100806BDBM100806(US8507533, 115 | US8507533, 330 | US8507533, 114)
Affinity DataKi:  7.60nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2390BDBM2390(US8507533, 146)
Affinity DataKi:  9.05nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100806BDBM100806(US8507533, 115 | US8507533, 330 | US8507533, 114)
Affinity DataKi:  15.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100796BDBM100796(US8507533, 101)
Affinity DataKi:  17nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100827BDBM100827(US8507533, 374 | US8507533, 151 | US8507533, 138)
Affinity DataKi:  20.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2376BDBM2376(US8507533, 137)
Affinity DataKi:  20.2nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100844BDBM100844(US8507533, 398 | US8507533, 160)
Affinity DataKi:  25.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2391BDBM2391(US8507533, 147)
Affinity DataKi:  26.7nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100850BDBM100850(US8507533, 168)
Affinity DataKi:  27.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100852BDBM100852(US8507533, 419 | US8507533, 170)
Affinity DataKi:  28nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100844BDBM100844(US8507533, 398 | US8507533, 160)
Affinity DataKi:  29nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100822BDBM100822(US8507533, 399 | US8507533, 162 | US8507533, 129)
Affinity DataKi:  29.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2241BDBM2241(US8507533, 136)
Affinity DataKi:  30.2nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100838BDBM100838(US8507533, 153)
Affinity DataKi:  32.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2240BDBM2240(US8507533, 135)
Affinity DataKi:  35nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100837BDBM100837(US8507533, 152)
Affinity DataKi:  35.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100805BDBM100805(US8507533, 113)
Affinity DataKi:  38.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2438BDBM2438(US8507533, 158)
Affinity DataKi:  41nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100861BDBM100861(US8507533, 188)
Affinity DataKi:  42.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100864BDBM100864(US8507533, 193)
Affinity DataKi:  44.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100815BDBM100815(US8507533, 122)
Affinity DataKi:  45.7nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100822BDBM100822(US8507533, 399 | US8507533, 162 | US8507533, 129)
Affinity DataKi:  47.3nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2229BDBM2229(US8507533, 448 | US8507533, 187)
Affinity DataKi:  47.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100824BDBM100824(US8507533, 131)
Affinity DataKi:  51nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100801BDBM100801(US8507533, 322 | US8507533, 109)
Affinity DataKi:  57.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2387BDBM2387(US8507533, 143)
Affinity DataKi:  57.4nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100826BDBM100826(US8507533, 133)
Affinity DataKi:  58nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100831BDBM100831(US8507533, 144)
Affinity DataKi:  62.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100829BDBM100829(US8507533, 140)
Affinity DataKi:  62.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100847BDBM100847(US8507533, 163)
Affinity DataKi:  65.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100797BDBM100797(US8507533, 105)
Affinity DataKi:  69.8nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100799BDBM100799(US8507533, 107)
Affinity DataKi:  71.6nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100856BDBM100856(US8507533, 181)
Affinity DataKi:  87.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100816BDBM100816(US8507533, 123)
Affinity DataKi:  88.4nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100830BDBM100830(US8507533, 141)
Affinity DataKi:  89.5nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100798BDBM100798(US8507533, 106)
Affinity DataKi:  91.9nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100794BDBM100794(US8507533, 300 | US8507533, 98 | US8507533, 97)
Affinity DataKi:  93nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100823BDBM100823(US8507533, 369 | US8507533, 130)
Affinity DataKi:  93.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2408BDBM2408(US8507533, 155)
Affinity DataKi:  94.9nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100818BDBM100818(US8507533, 125)
Affinity DataKi:  98.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100854BDBM100854(US8507533, 176)
Affinity DataKi:  101nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100812BDBM100812(US8507533, 119)
Affinity DataKi:  103nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100860BDBM100860(US8507533, 450 | US8507533, 189 | US8507533, 187)
Affinity DataKi:  109nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100817BDBM100817(US8507533, 124)
Affinity DataKi:  109nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 2232BDBM2232(US8507533, 134)
Affinity DataKi:  110nMAssay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100823BDBM100823(US8507533, 369 | US8507533, 130)
Affinity DataKi:  116nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100833BDBM100833(US8507533, 148)
Affinity DataKi:  125nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

TargetPro-glucagon(Human)
Pfizer

US Patent
LigandChemical structure of BindingDB Monomer ID 100825BDBM100825(US8507533, 132)
Affinity DataKi:  132nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/7/2013
Entry Details
US Patent

Displayed 1 to 50 (of 84 total ) | Next | Last >>
Jump to: